TabMenu

Poverty and InequalitySexual and Reproductive HealthFamily, Maternal & Child HealthMethodology

Integrating Clinical and Multiple Omics Data for Prognostic Assessment across Human Cancers

TitleIntegrating Clinical and Multiple Omics Data for Prognostic Assessment across Human Cancers
Publication TypeJournal Article
Year of Publication2017
AuthorsZhu, B, Song, N, Shen, R, Arora, A, Machiela, MJ, Song, L, Landi, MT, Ghosh, D, Chatterjee, N, Baladandayuthapani, V, Zhao, H
JournalSci Rep
Volume7
Pagination16954
Date PublishedDec 5
ISBN Number2045-2322
Accession Number29209073
Abstract

Multiple omic profiles have been generated for many cancer types; however, comprehensive assessment of their prognostic values across cancers is limited. We conducted a pan-cancer prognostic assessment and presented a multi-omic kernel machine learning method to systematically quantify the prognostic values of high-throughput genomic, epigenomic, and transcriptomic profiles individually, integratively, and in combination with clinical factors for 3,382 samples across 14 cancer types. We found that the prognostic performance varied substantially across cancer types. mRNA and miRNA expression profile frequently performed the best, followed by DNA methylation profile. Germline susceptibility variants displayed low prognostic performance consistently across cancer types. The integration of omic profiles with clinical variables can lead to substantially improved prognostic performance over the use of clinical variables alone in half of cancer types examined. Moreover, we showed that the kernel machine learning method consistently outperformed existing prognostic signatures, suggesting that including a large number of omic biomarkers may provide substantial improvement in prognostic assessment. Our study provides a comprehensive portrait of omic architecture for tumor prognosis across cancers, and highlights the prognostic value of genome-wide omic biomarker aggregation, which may facilitate refined prognostic assessment in the era of precision oncology.

PMCID

PMC5717223